Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Dualism of FGF and TGF-β Signaling in Heterogeneous Cancer-Associated Fibroblast Activation with ETV1 as a Critical Determinant

  • Pino Bordignon
  • , Giulia Bottoni
  • , Xiaoying Xu
  • , Alma S Popescu
  • , Zinnia Truan
  • , Emmanuella Guenova
  • , Lukas Kofler
  • , Paris Jafari
  • , Paola Ostano
  • , Martin Röcken
  • , Victor Neel
  • , G Paolo Dotto

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

Abstract

Heterogeneity of cancer-associated fibroblasts (CAFs) can result from activation of distinct signaling pathways. We show that in primary human dermal fibroblasts (HDFs), fibroblast growth factor (FGF) and transforming growth factor β (TGF-β) signaling oppositely modulate multiple CAF effector genes. Genetic abrogation or pharmacological inhibition of either pathway results in induction of genes responsive to the other, with the ETV1 transcription factor mediating the FGF effects. Duality of FGF/TGF-β signaling and differential ETV1 expression occur in multiple CAF strains and fibroblasts of desmoplastic versus non-desmoplastic skin squamous cell carcinomas (SCCs). Functionally, HDFs with opposite TGF-β versus FGF modulation converge on promoting cancer cell proliferation. However, HDFs with increased TGF-β signaling enhance invasive properties and epithelial-mesenchymal transition (EMT) of SCC cells, whereas HDFs with increased FGF signaling promote macrophage infiltration. The findings point to a duality of FGF versus TGF-β signaling in distinct CAF populations that promote cancer development through modulation of different processes.

OriginalspracheEnglisch
Seiten (von - bis)2358-2372.e6
FachzeitschriftCell Reports
Volume28
Ausgabenummer9
DOIs
PublikationsstatusVeröffentlicht - 27 Aug. 2019
Extern publiziertJa

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gute Gesundheit und Wohlergehen
    SDG 3 – Gute Gesundheit und Wohlergehen

Wissenschaftszweige

  • 302 Klinische Medizin

Dieses zitieren